XML 75 R9.htm IDEA: XBRL DOCUMENT
v3.19.3

Revenue (Notes) | 9 Months Ended
--- | ---
Sep. 30, 2019
Revenue from Contract with Customer [Abstract] |
Revenue from Contract with Customer [Text Block] | Revenue Our primary product lines are Infusion Consumables, IV Solutions, Infusion Systems and Critical Care. The vast majority of our sales of these products are made on a stand-alone basis to hospitals and distributors. Revenue is typically recognized upon transfer of control of the products, which we deem to be at point of shipment. Payment is typically due in full within 30 days of delivery or the start of the contract term. Revenue is recorded in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. We offer certain volume-based rebates to our distribution customers, which we record as variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time and our historical experience with each customer to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end-customers at prices determined under a contract between us and the end-customer. We use information available at the time and our historical experience to estimate and record provisions for chargebacks. We also warrant products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available at that time and our historical experience. We also provide for extended service-type warranties, which we consider to be separate performance obligations. We allocate a portion of the transaction price to the extended service-type warranty based on its estimated relative selling price, and recognize revenue over the period the warranty service is provided. Revenue disaggregated The following table represents our revenues disaggregated by geography (in thousands):
| For the three months ended September 30, |  | For the nine months ended September 30,
Geography | 2019 |  | 2018 |  | 2019 |  | 2018
Europe, the Middle East and Africa | $ | 31,474 |  |  | $ | 30,759 |  |  | $ | 96,830 |  |  | $ | 104,150 |
Other Foreign | 53,398 |  |  | 51,569 |  |  | 156,353 |  |  | 154,278 |
Total Foreign | 84,872 |  |  | 82,328 |  |  | 253,183 |  |  | 258,428 |
United States | 222,599 |  |  | 244,841 |  |  | 697,502 |  |  | 801,234 |
Total Revenues | $ | 307,471 |  |  | $ | 327,169 |  |  | $ | 950,685 |  |  | $ | 1,059,662 |
The following table represents our revenues disaggregated by product (in thousands):
| For the three months ended September 30, |  | For the nine months ended September 30,
Product line | 2019 |  | 2018 |  | 2019 |  | 2018
Infusion Consumables | $ | 119,745 |  |  | $ | 117,797 |  |  | $ | 357,994 |  |  | $ | 361,490 |
IV Solutions | 98,159 |  |  | 114,433 |  |  | 313,976 |  |  | 394,198 |
Infusion Systems | 78,932 |  |  | 81,456 |  |  | 244,523 |  |  | 263,271 |
Critical Care | 10,635 |  |  | 13,483 |  |  | 34,192 |  |  | 40,703 |
Total Revenues | $ | 307,471 |  |  | $ | 327,169 |  |  | $ | 950,685 |  |  | $ | 1,059,662 |
Contract balances The following table presents our changes in the contract balances for the nine months ended September 30, 2019 and 2018 (in thousands):
| Contract Liabilities
Beginning balance, January 1, 2019 | $ | (4,282 | )
Equipment revenue recognized | 3,619 |
Equipment revenue deferred due to implementation | (6,869 | )
Software revenue recognized | 2,955 |
Software revenue deferred due to implementation | (3,115 | )
Ending balance, September 30, 2019 | $ | (7,692 | )
Beginning balance, January 1, 2018 | $ | (7,066 | )
Equipment revenue recognized | 3,136 |
Equipment revenue deferred due to implementation | (4,086 | )
Software revenue recognized | 5,649 |
Software revenue deferred due to implementation | (5,507 | )
Ending balance, September 30, 2018 | $ | (7,874 | )
As of September 30, 2019, revenue from remaining performance obligations related to implementation of software and equipment is $6.3 million. We expect to recognize substantially all of this revenue within the next three months. Revenue from remaining performance obligations related to annual software licenses is $1.4 million. We expect to recognize substantially all of this revenue over the next twelve months.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration